Compare KLA Corp. (KLAC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? KLA Corp. trades at $208.41 (market cap $261.92B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: KLA Corp. pays a 0.46% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, KLA Corp. nearer its low. Which is the better fit depends on your goals.
| KLAC | XBI | |
|---|---|---|
Market Cap | $261.92B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $301.71 | $164.28 |
52-Week Low | $84.39 | $86.92 |
Enterprise Value | $263.17B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $208.27, up 8.06% on the day, reflecting strong momentum amid the AI-driven semiconductor equipment rally. The stock exhibits bullish technical signals with recent earnings beats and robust profitability, including a 35.57% net income margin. Recent corporate actions include a 1:10 stock split and dividend declarations, while analyst consensus leans heavily bullish with a $246.93 price target.
Outlook remains positive given KLAC's exposure to advanced packaging growth and AI chip demand, though elevated valuation ratios (P/E of 54.77) and technical overbought conditions near resistance at $209 pose near-term risks. Long-term investors may find value in its fundamental strength, but volatility from sector cyclicality warrants caution.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
